$OTLK - Norse 2, phase 3 trial was established and approved by the FDA to proceed based on the interim Norse 1 data The secondary endpoints from the subsequent Norse 1 trial showed superiority over Lucentis for treatment naive patients. The secondary endpoints that exceeded Lucentis endpoints in the Norse 1 trial are now the primary endpoints for the Norse 2 trial Norse 2 readout will show superiority over Lucentis as all the previously treated patients (non naive) patients were excluded from the Norse 2 trial For those with half a brain, it’s like fishing in a barrel.......$7 Billion+
  • 7
  • 1